Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HX-NC4-397
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Jinan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
HX-NC4-397 is a novel peptide-based PET tracer targeting Nectin-4, developed by Hexin Pharmaceutical in collaboration with the First Affiliated Hospital of Jinan University. Nectin-4 is a transmembrane adhesion molecule overexpressed in several solid tumors, including urothelial and breast cancers, while showing limited expression in normal adult tissues. Radiolabeled with gallium-68 to form ⁶⁸Ga-HX-NC4-397, the tracer is designed for noninvasive positron emission tomography (PET) imaging to visualize Nectin-4 expression. This supports patient stratification and treatment monitoring for Nectin-4-targeted therapies. In preclinical models and first-in-human clinical studies, ⁶⁸Ga-HX-NC4-397 demonstrated high radiochemical purity, specific tumor binding, and favorable tumor-to-background contrast, successfully identifying Nectin-4-expressing lesions in patients with breast cancer and urothelial carcinoma.
- Other names
- 68Ga-HX-NC4-397⁶⁸Ga-HX-NC4-397
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on HX-NC4-397.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HX-NC4-397.